EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Nancy Loos-van Kreel

Work experience

09-2024 - Present: Quality assessor at Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Assessment of chemical- and pharmaceutical aspects (Module 3) of a registration dossier.

01-2024 – 08-2024: Production pharmacist at the biotherapeutics unit of the Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Control of TIL product preparation protocols; CAPA; OOS registration; root-cause analysis

06-2019 – 12-2023: PhD student at AVL/NKI at the Pharmacology department, Amsterdam, The Netherlands
Title of the dissertation: Relevance of pharmacological boosters in the disposition of oral anticancer drugs – Mouse models

03-2019 – 06-2019: Project pharmacist at OLVG Oost, Amsterdam, The Netherlands
Day shifts, medication monitoring, oncolytics

06-2018 – 03-2019: Project pharmacist at Fundashon Mariadal, Kralendijk, Bonaire.
Day shifts, medication monitoring

08-2017 – 06-2018: Project pharmacist oncology at the Meander Medical Centrum, Amersfoort, the Netherlands
Validation and implementation of cytostatic monitoring system, medication monitoring

Education and training

06-2019 - 12-2023: PhD student at AVL/NKI at the Pharmacology department, The Netherlands. Graduation ceremony in April 2024 (Dr.)
Title of the dissertation: Relevance of pharmacological boosters in the disposition of oral anticancer drugs – Mouse models

09-2020 - 06-2023: Clinical pharmacologist training (NVKFB), education fulfilled in June 2023. Graduation after PhD ceremony in April 2024. Skills: pharmacology, patient care, regional and national medicines policy, toxicology, and science.

09-2014 - 07-2017: Master's in Pharmacy (Utrecht University), graduated (MSc).

09-2011 - 07-2014: Bachelor's in Pharmacy (Utrecht University), graduated (BSc).

09-2005 - 06-2011: Secondary education (Gymnasium, Herbert Vissers College, Nieuw-Vennep), graduated.

Additional information

Publications

Publications (as first author):

- ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Nancy H.C. Loos *et al.* Pharmacol. Res. 2022 Apr;178:106137. doi: 10.1016/j.phrs.2022.106137. Epub 2022 Feb 19.
- The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? Nancy H.C. Loos *et al.* Int. J. Mol. Sci. 2022 Aug 30;23(17):9866. doi: 10.3390/ijms23179866.
- Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice. Nancy H.C. Loos *et al.* Mol. Pharm. 2023 May 1;20(5):2477-2489. doi: 10.1021/acs.molpharmaceut.2c01076. Epub 2023 Mar 28.
- The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Nancy H.C. Loos *et al.* Biomed. Pharmacother. 2023 Jun;162:114636. doi: 10.1016/j.biopha.2023.114636. Epub 2023 Apr 1.
- Complications in post-mortem GHB cut-off values in urine samples: A case report. N.H.C. Loos *et al.* Toxicol. Rep. 2023 May 9;10:600-603. doi: 10.1016/j.toxrep.2023.05.002. eCollection 2023.
- Pharmacokinetics of the $KRAS^{G12C}$ inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c. Nancy H.C. Loos *et al.* Biomed Pharmacother. 2023 Aug 14;166:115304. doi: 10.1016/j.biopha.2023.115304.
- Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice. Nancy H.C. Loos *et al.* Int J Pharm. 2024 Jan 25:650:123708. doi: 10.1016/j.ijpharm.2023.123708. Epub 2023 Dec 20.
- Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Nancy H.C. Loos *et al.* Mol. Pharm. 2024 Apr 1;21(4):1952-1964. doi: 10.1021/acs.molpharmaceut.3c01205. Epub 2024 Feb 29.
- Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment. Nancy H.C. Loos *et al.* Cancer Chemother. Pharmacol. 2024 Jul;94(1):79-87. doi: 10.1007/s00280-024-04662-8. Epub 2024 Mar 8.
- The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib. Nancy H.C. Loos *et al.* Toxicol. Appl. Pharmacol. 2024 Apr: 485:116911. doi: 10.1016/j.taap.2024.116911. Epub 2024 Mar 26.

Projects

Memberships	
Other Relevant Information	Inventor on the patent (publication number: 20240226072; publication date: July 11, 2024) for Combination treatment for solid tumors using cabazitaxel and a CYP3A inhibitor.